IL18 and diabetes mellitus: Consistently, drug-naïve type 2 DM patients had higher IL-1β and IL-18 serum levels compared with healthy subjects, and in vitro knockdown of NLRP3 in monocytes of DM patients prevented the ability of metabolic DAMPs to induce IL-1β and IL-18 secretion [7].